Please use this identifier to cite or link to this item: http://hdl.handle.net/11054/1395
Full metadata record
DC FieldValueLanguage
dc.contributorNorris, Jeanen_US
dc.contributorBarker, Jamesen_US
dc.contributorBuelens, Odetteen_US
dc.contributorSpruijt, Odetteen_US
dc.date.accessioned2019-10-14T08:32:30Z-
dc.date.available2019-10-14T08:32:30Z-
dc.date.issued2019-
dc.identifier.govdoc01361en_US
dc.identifier.urihttp://hdl.handle.net/11054/1395-
dc.description.abstractAbstract Background: Intractable pruritus affects an estimated 83% of patients with advanced cutaneous T-cell lymphoma. Palliative care strategies to improve outcomes for these patients are lacking. Lignocaine antagonises kappa opioid antagonist-induced scratching in mice models and may relieve cutaneous T-cell lymphoma–pruritus.Practice challenge: The aim of this retrospective case series was to evaluate our clinical experience with low-dose continuous subcutaneous infusion lignocaine for intractable pruritus associated with cutaneous T-cell lymphoma, from 2000 to 2015. The study received approval from Retrospective Review Panel, Division Cancer Medicine, 12 October 2015, V1.1. Method: Baseline demographics including cutaneous T-cell lymphoma diagnosis and management, comorbidities, and pruritus-related evaluation including onset, severity, past and current therapies were collected. Response categories (Complete, Partial, No, Unknown) were devised for the study, based on severity of pruritus, impact on sleep and mood. The mean of responses was calculated for each patient and across the series. Outcome: Nineteen patients received continuous subcutaneous infusion lignocaine, in 45 treatment episodes, ranging from 1 to 70 days (interquartile range = 5). Baseline mean number of adjuvants was 3.9 (range, 1–9). Across the series, complete response was achieved, on average, 26.7% days, partial response 49.4%, no response 16.1% and unknown response 9.2%. Drowsiness was documented in four patients. Three patients died during continuous subcutaneous infusion due to disease progression. Lessons: Continuous subcutaneous infusion lignocaine offers another therapeutic option in cutaneous T-Cell lymphom–related intractable pruritus. Future research: Prospective studies using validated assessment tools and systematic approaches to pruritus management are required.en_US
dc.description.provenanceSubmitted by Gemma Siemensma (gemmas@bhs.org.au) on 2019-07-16T04:14:47Z No. of bitstreams: 0en
dc.description.provenanceApproved for entry into archive by Gemma Siemensma (gemmas@bhs.org.au) on 2019-10-14T08:32:30Z (GMT) No. of bitstreams: 0en
dc.description.provenanceMade available in DSpace on 2019-10-14T08:32:30Z (GMT). No. of bitstreams: 0 Previous issue date: 2019en
dc.relation.uriDOI:10.1177/0269216319828189en_US
dc.titleDoes continuous subcutaneous infusion of lignocaine relieve intractable pruritus associated with advanced cutaneous T-cell lymphoma? A retrospective case series review.en_US
dc.typeJournal Articleen_US
dc.type.specifiedArticleen_US
dc.bibliographicCitation.titlePalliative Medicineen_US
dc.bibliographicCitation.volume33en_US
dc.bibliographicCitation.issue5en_US
dc.bibliographicCitation.stpage552en_US
dc.bibliographicCitation.endpage556en_US
dc.subject.healththesaurusLIGNOCAINE/IIODOCAINEen_US
dc.subject.healththesaurusCONITNUOUS SUBCUTANEOUS INFUSIONen_US
dc.subject.healththesaurusCUTANEOUS T-CELL LYMPHOMAen_US
dc.subject.healththesaurusMYCOSIS FUNGOIDESen_US
dc.subject.healththesaurusPRURITISen_US
dc.subject.healththesaurusRETROSPECTIVEen_US
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.